上海澳华内镜股份有限公司 2025 年第一次临时股东大会会议资料 证券简称：澳华内镜 证券代码：688212 上海澳华内镜股份有限公司 2025 年第一次临时股东大会 会议资料 二零二五年六月 上海澳华内镜股份有限公司 2025 年第一次临时股东大会会议资料 上海澳华内镜股份有限公司 会议资料目录 | 2025 年第一次临时股东大会会议须知 | 1 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 3 | | 关于《上海澳华内镜股份有限公司 2025 | 年员工持股计划（草案）》及其摘要的议案 4 | | 关于《上海澳华内镜股份有限公司 2025 | 年员工持股计划管理办法》的议案 5 | | 关于提请股东大会授权董事会办理上海澳华内镜股份有限公司 | 2025 年员工持股计划有关事 | | 项的议案 | 6 | 上海澳华内镜股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 中国证监会《上市公司股 ...

Core Viewpoint - Aohua Endoscopy (688212.SH) announced a plan for major shareholders to reduce their holdings by up to 1,252,840 shares, representing 0.93% of the total share capital, through centralized bidding and block trading methods [1][2]. Shareholding Structure - As of the announcement date, Gu Kang, Gu Xiaozhou, and their controlled entity, Shanghai Xiaozhou Optoelectronics Co., Ltd. (Xiaozhou Optoelectronics), collectively hold 41,822,800 shares, accounting for 31.06% of the total share capital [2][3]. - Xiaozhou Optoelectronics holds 3,132,100 shares (2.33%), Gu Kang holds 16,950,200 shares (12.59%), and Gu Xiaozhou holds 21,740,500 shares (16.14%) [2]. Reasons for Share Reduction - The share reduction is attributed to the funding needs of Su Min Investment Junxin (Shanghai) Industry Upgrade and Technology Innovation Equity Investment Partnership (Limited Partnership), a shareholder of Xiaozhou Optoelectronics [3]. Financial Performance - In 2024, Aohua Endoscopy achieved a revenue of 750 million yuan, a year-on-year increase of 10.54%, while the net profit attributable to shareholders dropped by 63.68% to 21 million yuan [4][5]. - The net cash flow from operating activities was negative at -78.93 million yuan [5]. - For Q1 2025, the company reported a revenue of 124 million yuan, a decline of 26.92%, and a net loss attributable to shareholders of -28.79 million yuan [6][7].

Core Viewpoint - The company Shanghai Aohua Endoscope Co., Ltd. is holding an investor briefing on May 29, 2025, to discuss its Q1 2025 financial results and operational performance, allowing for interactive communication with investors [1][2]. Group 1: Meeting Details - Meeting Date and Time: May 29, 2025, from 15:00 to 16:00 [2] - Meeting Location: Shanghai Stock Exchange Roadshow Center [2] - Meeting Format: Online interactive session [2] Group 2: Participants - Attendees include the Chairman and General Manager Gu Xiaozhou, Vice General Manager and Board Secretary Shi Xiaojing, and Board Member and Financial Officer Qian Chenghao [2]. Group 3: Investor Participation - Investors can participate online on May 29, 2025, through the Shanghai Stock Exchange Roadshow Center [2] - Investors can submit questions from May 23 to May 28, 2025, via the Roadshow Center website or the company's email [2][3]. Group 4: Contact Information - Contact Department: Securities Affairs Department [3] - Phone: 021-54303731 [3] - Email: ir@aohua.com [3] Group 5: Additional Information - After the investor briefing, participants can view the meeting's details and main content on the Shanghai Stock Exchange Roadshow Center [3].

Group 1 - The core point of the announcement is that major shareholders of Shanghai Aohua Endoscopy Co., Ltd. plan to reduce their holdings by a total of up to 1,252,840 shares, which is approximately 0.93% of the company's total share capital [1][9] - The shareholders involved in the reduction are Gu Kang, Gu Xiaozhou, and their controlled entity, Shanghai Xiaozhou Optoelectronics Technology Co., Ltd., which collectively hold 41,822,800 shares, accounting for 31.06% of the company's total shares [2][9] - The reduction will be executed through centralized bidding and block trading methods, with the reduction period starting 15 trading days after the announcement and lasting for three months [1][4] Group 2 - The reason for the share reduction is attributed to the funding needs of Su Min Investment Junxin (Shanghai) Industrial Upgrade and Technological Innovation Equity Investment Partnership (Limited Partnership), a shareholder of Xiaozhou Optoelectronics [2][9] - The major shareholders have committed not to participate in this reduction, ensuring that their indirect holdings through Xiaozhou Optoelectronics will not be affected [2][9] - The announcement confirms that the reduction plan complies with relevant laws and regulations, and it will not impact the company's governance structure or ongoing operations [9]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-042 上海澳华内镜股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 控股股东及其一致行动人持股的基本情况 截至本公告披露日，顾康、顾小舟及其控制的上海小洲光电科技有限公司（以 下简称"小洲光电"）合计持有上海澳华内镜股份有限公司（以下简称"公司"） 41,822,800 股，占公司总股本的 31.06%。其中小洲光电持有公司股份 3,132,100 股，占公司总股本的 2.33%；顾康持有公司股份 16,950,200 股，占公司总股本 的 12.59%；顾小舟持有公司股份 21,740,500 股，占公司总股本的 16.14%。上述 股份来源均为公司首次公开发行前取得的股份，且已于 2024 年 11 月 15 日起上 市流通。 减持计划的主要内容 公司于近日收到顾康、顾小舟及其控制的小洲光电出具的告知函，小洲光电 拟通过集中竞价交易方式、大宗交易方式合计减持数量不超过 1,252 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-041 上海澳华内镜股份有限公司 关于召开2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 29 日（星期四） 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 23 日（星期五）至 5 月 28 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aohua.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海澳华内镜股份有限公司（以下简称"公司"）已于2025年4月18日发布 公司2025年第一季度报告，为便于广大投资者更全面深入地了解公司2025年第 一季度经营成果、财务状况，公司计划于2025年5月29日（星 ...

Group 1 - The core point of the article is that the major shareholder, Xiaozhou Optoelectronics, of Aohua Endoscopy (688212.SH) plans to reduce its stake by up to 0.93% through various trading methods [1] - Xiaozhou Optoelectronics intends to sell a total of no more than 1,252,840 shares, which represents a maximum of 0.93% of the company's total share capital [1] - The reduction period for the shareholding will be within three months starting from 15 trading days after the announcement date [1]

Group 1 - Major shareholder Xiaozhou Optoelectronics plans to reduce its holdings by up to 1.2528 million shares, accounting for 0.93% of the company's total share capital [1] - The reduction period is set from June 16, 2025, to September 15, 2025 [1] - The reason for the reduction is due to the funding needs of Xiaozhou Optoelectronics' shareholder Su Min Investment Junxin [1]

Group 1: Company Overview - In 2024, the company's revenue was 749.5 million, representing a year-on-year growth of 10.53% [2] - The net profit attributable to shareholders was 20.1 million, showing a year-on-year decline of 63.68% [2] - The net profit after deducting non-recurring gains and losses was -6.2861 million, a year-on-year decrease of 114.13% [2] Group 2: Financial Metrics - Total sales expenses for the year amounted to 250 million, while research and development expenses were 164 million [2] - The company's gross margin was affected by the adoption of new accounting standards and an increase in overseas revenue, which generally has a lower gross margin compared to domestic operations [2] Group 3: Business Strategy and Market Position - The company aims to become a globally influential endoscope brand by enhancing product performance and brand recognition [2] - The overseas business is still in the early stages of development, with a diverse product mix and a higher proportion of low-to-mid-priced products, leading to lower gross margins compared to domestic operations [2] - The company is actively expanding its overseas market presence, particularly in Europe and other cost-effective markets, where there is incremental demand for soft endoscopes [2] Group 4: Industry Insights - The importance of endoscopic diagnosis is emphasized, as early screening of the digestive tract can significantly improve patient survival rates and quality of life [2] - The clinical demand for respiratory endoscopy is gradually emerging, with the company planning to track developments in this area closely [2]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-040 上海澳华内镜股份有限公司 关于调整2024年度利润分配现金分红总额的公告 本次调整原因：上海澳华内镜股份有限公司（以下简称"公司"）自 2024年年度利润分配方案披露之日至本公告披露日，因通过上海证券交易所交 易系统以集中竞价交易方式回购公司股份，导致公司回购专用证券账户中股份 总数发生变动，故本次实际参与分配的股份数发生变动，可参与利润分配的股 本数由133,939,669股减少至132,166,179股。根据公司2024年年度利润分配方 案，按照维持每股分配比例不变的原则，相应调整分配总额。 一、调整前利润分配方案 公司于2025年4月8日召开第二届董事会第十七次会议和第二届监事会第十 六次会议，于2025年5月8日召开2024年年度股东大会，分别审议通过了《关于 公司2024年度利润分配方案的议案》，公司以实施权益分派股权登记日登记的 总股本扣除回购专用账户中的股份为基数，向全体股东每10股派发现金红利0.8 元（含税），不进行资本公积转增股本，不送红股。如在分配方案披露之日起 至实施权益分派股权登记日期间，因可转债转股、回购股份、 ...